RxDoctor Payments Data

Michael Cher, MD

Urology · Detroit, MINPI 1336187400

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (52.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Merck at 38.1% of the total. Reporting peaked in 2023 at $3,058 and has fallen 74.8% since, to $769 in 2025.

$12,287in general payments, 2019–2025

Across 93 payments — averaging $132.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$5K
  • Intuitive Surgical$3K
  • Astrazeneca UK Limited$1K
  • Janssen Scientific Affairs, LLC$875
  • Olympus America Inc.$717
  • Pfizer$447
  • plus $2K from 17 others
$119,742in research payments, 2019–2025

Across 26 payments — averaging $4605.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Blue Earth Diagnostics$120K

What the payments were for

  • Consulting fees$6,46453%
  • Travel & lodging$2,09217%
  • Food & beverage$2,04617%
  • Education$9838%
  • Other$7026%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,287 in reported general payments places this provider in the 80th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$67,095
Medicare patients
225
Services billed
869

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide20$278,940
Abiraterone Acetate22$128,564
Mirabegron ErMirabegron12$5,399
MyrbetriqMirabegron12$4,965
Tamsulosin Hcl100$1,820
Finasteride57$1,483
Oxybutynin Chloride ErOxybutynin Chloride28$352
Prednisone15$106
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim21$39
Cephalexin13$27

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$139$283,90632 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$875$128,56422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 400 urology providers in Michigan.

Other urology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →